Humanin
Humanin • Also called Humanin Peptide
Humanin is a mitochondria- and longevity-focused peptide that shows up in biohacking discussions, but we do not currently have a clear FDA compounding category or approved-drug path for it.
Current status
Restricted
Longevity and mitochondrial interest, with current federal compounding constraints still in play.
FDA category
No clear FDA signal
Can pharmacies compound this?
No
Reclassification expected?
Unclear
FDA substance records can identify a peptide chemically without implying any approval or compounding authorization, which is the situation here.
Primary Use
Longevity and mitochondrial interest
Also searched as
Humanin Peptide
Regulatory Timeline
Mar 23, 2026
Current status signal recorded: No clear FDA category or approved-drug pathway identified; FDA substance registry presence does not imply regulatory approval or a lawful compounding basis..
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Humanin status changes
State-specific notes
Florida
Biohacking interest does not substitute for a documented compounding pathway.